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http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract This study aimed to investigate the clinical application value of the 5-fluorouracil
(5-FU) sustained-release particles implanted along the cardiac tangent direction into malig-
nant pericardial effusion (MPCE). A total of 81 MPCE patients underwent pericardiocentesis,
and were implanted with 5-FU sustained-release particles into the pericardial cavity under ul-
trasound guidance. The puncturing path was along the cardiac tangent direction. Ultrasound
examinations were performed every week, and the efficacy was evaluated 4 weeks after treat-
ment. The 45 patients who were treated with pericardial catheter drainage and simultaneous
intracavitary chemotherapy were used as the control group. The success rate of pericardio-
centesis was 100%. Ultrasound reviews performed 4 weeks after treatment showed that 71
cases achieved complete remission and eight cases achieved partial remission, while treat-
ment was completely ineffective in two cases. The total remission rate was 97.53%, which
was significantly higher than that of the control group (77.78%, p < 0.01). The implantation
of 5-FU sustained-release particles along the cardiac tangent direction was safe, and demon-
strated good efficacy and fewer adverse reactions. Thus, this method could be ideal for the
treatment of MPCE.
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Figure 1. The metastatic lesion can be seen in the
pericardium.
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Malignant pericardial effusion (MPCE) is a common clinical
manifestation in patients with advanced malignant cancers
that seriously affect the prognosis. The effective control of
pericardial effusion is significant at alleviating the suffering
of patients and prolonging their lives. Pericardiocentesis,
accompanied with catheter drainage (CD) and intracavitary
chemotherapy, is the main treatment method for MPCE. In
recent years, China has independently developed implant-
able sustained-release fluorouracil, which has been applied
for the treatment of various malignant tumors or preven-
tion of metastasis and recurrence, and achieved certain
positive effects [1,2]. Many scholars have applied this
method during surgery for various gastrointestinal cancers
[3]. Some scholars have also made useful attempts in the
treatment of liver cancer [4], pancreatic cancer, breast
cancer, and ovarian cancer [5]. Numerous studies have
shown that 5-fluorouracil (5-FU) sustained-release implan-
tation dose has good safety and efficacy in the treatment of
malignant pleural effusions and malignant ascites, espe-
cially in palliative treatment [6]. As for its treatment, the
currently widely-accepted strategy during the emergency
was rapid pericardial puncture, fluid-drainage-
decompression and saving lives, and the regeneration of
the effusion should be controlled or suppressed, which is
the current clinical research hotspot. In this study, 5-FU
particles instead of other chemotherapeutic drugs were
imported into pericardial cavity by ultrasonic intervention
technology to treat MPCE. This method is a novel explora-
tion in the ultrasonic intervention field. In this study, a
particle implantation (PI) needle was used to pierce
through the skin and into the pericardial cavity, completing
the processes of pumping fluid and implanting medicine.
The pericardium was decompressed, and etiological treat-
ment was simultaneously performed, which achieved good
results. A preliminary summary regarding the treatment of
81 cases of MPCE patients is reported in this paper.
Patients and methods
Case selection
A total of 81 hospitalized patients (PI group: comprised 33
males and 48 females, mean age, 61 years), suffering from
pericardial metastasis of late malignant tumors and
different levels of pericardial effusion, were selected from
the Shengli Oil Field Center Hospital from October 2006 to
October 2011. The KPS scores of the PI group ranged from
20 points to 50 points, with an expected survival duration >
2 months. The primary tumors were pathologically
confirmed, included 44 cases of lung cancer, 11 cases of
breast cancer, 11 cases of gastrointestinal cancer, six cases
of ovarian and cervical cancer, and nine cases of other
malignancies. The selected cases suffered from a large or
very large surrounding pericardial effusion, in which the
width of the nonecho region was 2.0e6.0 cm, and accom-
panied with a swinging heart. Eight cases exhibited peri-
cardial metastases or irregular thickening of the parietal
pericardium (Fig. 1), and 73 cases exhibited pleural effu-
sion (90%).A total of 45 patients (25 males and 20 females with an
average age of 59 years old) underwent pericardial CD and
intracavitary chemotherapy during the same period, and
they were established as the controls (CD group). Among
these 45 cases, 23 were of lung cancer, nine were of breast
cancer, six were of gastrointestinal cancer, one was of
ovarian cancer, and six were of other malignancies. All the
CD patients had large or extremely large surrounding peri-
cardial effusion.
Equipment
A DU8 and DU6 color Doppler ultrasonic diagnostic apparatus
(Esaote Group Co., Genoa, Italy), with a convex array probe
(2.5e7.0 MHz) and/or linear array probe (5.0e10 MHz), was
used as the intervention monitoring and guiding device. An
angle-fixed side-type titanium guiding device, which was
provided by the ultrasound machine manufacturer (angles
of 20, 25, 30, 35, and 45), was used as the puncturing
guide. An 18-gauge particle-implantation (PI) dedicated
needle (outer diameter 1.2 mm, internal diameter 1.0 mm)
was used in the apparatus.
Drugs
The drugs used were sustained-release 5-FU (Wuhu Zhong-
ren Pharmaceutical Co., Ltd., Wuhu, China), which has the
trade name of Sinofuan (Approval No: H20030345). This
drug is a long-term antitumor formulation, and appear as a
milk-white cylinder-like particle. The diameter of each
particle is 0.8 mm, length 4 mm. Each particle contains
approximately 2 mg of 5-FU, and 100 mg for each unit. The
releasing period ranges from 15 days to 20 days [7].
Puncturing path
To improve the safety of paracentesis, the cardiac tangent
or approximately tangent direction was established as the
puncturing path (denoted as the cardiac tangent direction)
under real-time ultrasonic guidance, which would avoid the
possibility of heart damage.
The puncturing point was preoperatively located at the
place where the pericardial effusion volume was relatively
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was used in determining the right puncturing path to ensure
that the puncturing path maintained the tangent or
approximately tangent direction towards the heart in this
region (Fig. 2). The puncturing angle (20e45) was then
fixed, and the puncturing point marked on the body skin
surface.
Preoperative preparation
Before puncturing, the patient’s medical history should be
learned to determine the cause of pericardial effusion.
Moreover, the patient should not have recently consumed
anticoagulant drugs and not have undergone hemodialysis,
to avoid uncontrollable bleeding after puncture. Preoper-
ative examinations of blood pressure, electrocardiogram
must be performed, blood routine, and blood coagulation
must also be performed to confirm the platelet count and
clotting time of the patient. Communication should be
carried out with patients and their families preoperatively
to explain the disease and inform the risks for informed
consent. Preoperative ultrasound examination should be
performed to understand the patient’s general condition,
and assess the extent of pericardial effusion. During the
surgery, the clinician should accompany the patient during
the entire period, and establish intravenous access. More-
over, the clinician should prepare the necessary rescue
medications, cardiac defibrillator, and other rescue equip-
ment to correct unexpected situations.
Procedure
The patient was asked to lie in the supine, semirecumbent,
or sitting position. Then, 2% lidocaine was injected for local
anesthesia. The 18-gauge PI needle was punctured along
the guiding line on an ultrasonic wave display screen using
the Seldinger technique. When the parietal pericardium
was pierced, the needlepoint, which displayed the equal
echo status, was in the dark area of the pericardial liquid.
The needle body then continued to advance by 2.0e3.0 cm.
The fluid could be seen when the needle core was pulled
out. Subsequently, the needle handle was rapidlyFigure 2. Image of the puncturing along the cardiac tangent.connected with the extension tube for slow drainage. The
amount of the first drainage was determined by the peri-
cardial pressure, and was usually 100 mL. This amount was
limited by the balance of intrapericardial pressure and at-
mospheric pressure to avoid the negative suction pressure
state. After drainage, the pericardial cavity pressure was
observed immediately. If the inside and outside pericardial
pressures were equal, the 5-FU sustained-release chemo-
therapy particles could be implanted. The extension tube
was removed, and 400 mg of 5-FU sustained-release parti-
cles was implanted into the pericardial cavity. After im-
plantation, a secondary drainage was performed (Fig. 3),
which was stopped when the remaining amount of effusion
was about 20e25% of the total amount. After completing
the surgery, the needle was removed. Then, the opening
was sealed with sterile dressing.
Efficacy evaluation
No uniform international standard towards the efficacy
evaluation of MPCE currently exists. Based on the tumor
efficacy evaluation criteria and RECIST (2000) evaluation of
the nontarget lesions by the World Health Organisation [8],
the efficacy was evaluated according to the following
criteria after treatment: (1) complete remission (CR), in
which pericardial effusion completely disappeared or left
trace remnants, and the clinical symptoms were signifi-
cantly relieved and maintained for > 30 days; (2) partial
remission (PR), in which pericardial effusion was reduced
by > 50%, and the clinical symptoms and signs were
partially remitted and maintained for > 30 days; and (3) no
response, in which the situation did not meet the above
criteria, and the pericardial tamponade symptoms achieved
no relief or increased. The total efficiency was calculated
using the following formula: total efficiency Z (CR
number þ PR number)/total number of cases  100%.
After the treatment, ultrasound examination was per-
formed once every 5e7 days to observe the changes in
pericardial effusion. Other treatments were performed in
the invalid or progressed patients, whereas the patientsFigure 3. Puncturing was carried out along the approximate
tangent direction of the pericardial effusion, partial liquid was
extracted, 5-fluorouracil sustained-release particle was
implanted, and then 600 mL liquid was extracted again.
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examination was performed for the efficacy evaluation 4
weeks after treatment.
Statistical analysis
SPSS 13.0 was used for statistical analysis, and intergroup
comparisons were made using c2 test. A p-value < 0.05 was
set as statistical significance.
Results
Puncturing results
All 81 cases underwent puncturing successfully the first
time. Among these cases, 69 had bloody effusion (85.19%),
whereas 12 had pale yellow or yellow effusion (14.81%).
After the effusion was centrifuged, 57 cases were found
positive for tumor cells (70.37%). The total drainage volume
was 300e1500 mL before and after drug implantation, and
the average volume was approximately 900 mL.
Short-term efficacy evaluation
The postoperative 1st week ultrasound results show no
growth in the residual fluid volume after drainage in all
cases. The postoperative 2nd week ultrasound results show
that 71 cases exhibited a significant reduction in the re-
sidual liquid (liquid width was 5e10 mm), eight cases
exhibited slight decrease in the residual liquid (liquid width
was 10e15 mm) and two cases showed no significant
changes in the residual liquid. The postoperative 3rd week
ultrasound results show that 71 cases exhibited a significant
reduction in residual fluid compared to the 2nd week.
Among these 71 cases, 45 cases exhibited the complete
disappearance of residual liquid (Fig. 4), whereas 26 still
exhibited trace or small amounts of fluid (liquid width was
4e8 mm). The amount of residual liquid of the other eightFigure 4. Pericardial effusion almost disappeared 20 days
after treatment.cases continued to decrease (liquid width was 8e12 mm),
whereas no noticeable change was observed in the amount
of residual liquid in the other two cases.
According to established clinical evaluation criteria, an
ultrasound examinationwas performed on the postoperative
4th week to evaluate the short-term effects. The 71 cases in
which residual effusion completely disappeared or only
trace fluid remained were identified as CR. Eight cases were
identified as PR because their effusion decreased, but little
or moderate amount of fluid still remained. Two cases were
identified as no response because no postoperative reduc-
tion of effusion was observed. In these two cases, one pa-
tient had renal carcinoma, and the other had high-position
cholangiocarcinoma. These two patients were given peri-
cardial CD.
Efficacy comparison
The total effective rate of MPCE PI therapy was 97.53%,
which was higher than CD (77.78%), with p < 0.01 (Table 1).
Adverse reactions
Three patients complained of palpitation and chest tight-
ness on the day after the surgery, with a pulse > 120 beats/
min. These symptoms improved after oxygen inhalation and
oral administration of metoprolol. Shock or fever did not
occur in any of the cases.Discussion
MPCE is a common complication in patients with advanced
cancers, and about one-third of MPCE patients eventually
die because of clinical cardiac tamponade. MPCE is often
bloody, has a large volume and fast growth speed and is
difficult to control. Early diagnosis and treatment can
significantly improve the symptoms, and provide opportu-
nities for the next step of treatment. The current clinical
approach commonly used is based on minimally invasive
intervention, such as pericardial paracentesis or CD, than
local methods, such as cavity medication (including bio-
logical immunosuppressive agents, herbal preparations,
chemotherapy drugs, hardening agent, and targeting
agents) and cavity hyperthermia.
The method of pericardiocentesis for CD, combined
with intracavitary local chemotherapy or
chemotherapy þ biological response modifier, has been
applied for many years. The drugs injected include drugs
with relatively small cardiotoxicity, such as cisplatin, car-
boplatin, 5-FU and mitomycin. Research [8] has shown that
pericardiocentesis for CD, plus intracavitary local chemo-
therapy, can reduce the systemic side effects with high
efficacy compared with intravenous chemotherapy. This
method can greatly improve the body’s tolerance against
anticancer drugs, and the body’s immune function is less
affected. However, given the efficacy of chemotherapy
drugs, the aqueous dosage form can only be maintained for
several hours, and the use of a catheter may be inconve-
nient. Thus, the clinical application of this method is
limited to some degree.
Table 1 Efficacy comparison of particle implantation (PI) and catheter drainage (CD) [n (%)].
Grouping Cases CR PR NR Total efficacy
PI 81 71 (87.65) 8 (9.88) 2 (2.47) 79 (97.53)
CD 45 19 (42.22) 16 (35.56) 10 (22.22) 35 (77.78)
c2 test c2 Z 10.91, p < 0.01
CR Z complete remission; NR Z no response; PR Z partial remission.
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which is currently the most widely used clinical sustained-
release agent, is made of antipyrimidine drugs, and has
dual characteristics of sustained-release and targeting. In
the pericardial cavity, this method can maintain the
effective concentration of drugs for a long period to
enhance the anticancer effects, and does not result in
serious adverse reactions. During the implantation proce-
dure and postoperative ultrasound in this study, 5-FU
sustained-release particles floated in the effusion, and
exhibited a state of motion caused by the heartbeat. The
implanted particles gathered locally, and the efficacy was
unaffected because of the postural changes. The 5-FU dose
used in the previous intracavitary chemotherapy was also
used in this study, and 400 mg of sustained-release particles
containing the appropriate content of 5-FU were selected
and implanted into the pericardium. This method achieved
good results with total efficiency of 97.53% and CR rate of
87.65%, which were significantly higher than those of CD
(p < 0.01).
Pericardiocentesis combined with implantation of a
sustained-release chemotherapeutic agent is a new explo-
ration in interventional therapy. Three puncturing sites and
paths are generally used. In the xiphoid process-inferior
path, the puncturing site is 1 cm below the cross of the left
costal margin and left edge of xiphoid process. The punc-
ture needle is 30e45 against the abdominal wall, with the
tip pointing to the left nipple, and the puncturing depth is
about 4.0e6.0 cm. In the second path, the puncturing site
is 2.0 cm from the fourth rib to the left sternal border. The
needle is perpendicular to the chest wall, and the punc-
turing depth is 2.0e4.0 cm. The path is equivalent to the
bare area of the pericardium. In the third path, the punc-
turing site is 2.0 cm inside the cardiac dullness of the left
fourth intercostal space. The needle is pointed backwards,
and the inner direction is pointed to the spine. The punc-
turing depth is 2.0e4.0 cm. By contrast, pericardiocentesis
performed in the bare area of the pericardium is the safest
site because the fibrous pericardium is directly stuck to the
chest wall [9], vertical puncturing does not affect the
pleural cavity and puncturing distance is the shortest.
However, pericardiocentesis in this site has smaller choice
space. Moreover, this site is often not considered in elderly
patients because of the narrow intercostal space, and
puncturing needs to be vertical or nearly vertical against
the chest wall. Furthermore, the heart wall and coronary
artery may be injured with fluid reduction when draining
effusion. The aforementioned three puncturing paths are
suitable when the heart does not exhibit shifting, and no
resistance/obstacle exists between the chest wall and
intercostal space. However, in real clinical situations,special cases are often encountered, such as the pulling
and shifting of the heart of lung resection patients to the
operation side. Such cases have a greater risk in puncturing
the pericardium based on the conventional path. If a tumor
invades the ribs after rib resection surgery, the titanium
plate would be implanted into the rib-absent area, and the
conventional route for pericardiocentesis would be
inappropriate.
This study attempted to perform pericardiocentesis
along the cardiac tangent direction. The heart and peri-
cardium constitute a morphological structure similar to an
irregularly shaped cone or pear. Sternocostal scanning
revealed that any of its cross-sections can be considered as
arc or near-arc, particularly with a large or very large
amount of pericardial effusion. Moreover, the separation
width between the two splanchnic walls can increase, thick
liquid can surround or wrap the epicardium surface, the
amount of liquid in front of the heart is often more than
that behind the heart and the widest region is often located
in the apical point. With the increase in pericardial effu-
sion, the arc of the ultrasonic cross-section would corre-
spondingly increase, and create viable conditions for
searching the heart tangent or approximate tangent di-
rection. These ultrasonographic features of MPCE are the
anatomical basis of establishing the heart tangent or nearly
tangent direction as the pericardiocentesis path.
Pericardiocentesis through the heart tangent direction
must have accurate ultrasound guidance. The direct view
of ultrasound imaging clearly displays every step. In the
process of draining, the heart walls and coronary arteries
are unaffected even when effusion decreases.
The accurate puncturing site and path are highly
important in pericardiocentesis through the heart tangent
direction. Locating the heart tangent or approximate
tangent direction and a suitable puncturing site are
essential to successful puncturing. During the operation,
several points should be noted. Firstly, probe selection
should be flexible for the patients with the extended
resection of left breast because the chest wall is thinner. A
smaller convex or linear high-frequency probe can be used
to reduce the blind spots and obtain clear guidance image.
Secondly, the image should be appropriately enlarged when
necessary to facilitate clear display of the tip. Thirdly, the
image enhancement technology inside the machine should
be applied, such as diamond imaging technology and har-
monic technology, to obtain higher quality images for
facilitating guidance. Fourthly, the needle body should be
continuously moved forward by 2.0e3.0 cm when breaking
through the pericardium, and the beating heart should not
be stabbed when effusion draining reduces the pericardium
separation width. Fifthly, draining should be slow because
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Heart failure or pulmonary edema would appear when
pressure suddenly reduces. Sixthly, the sequence should be
puncturingedrainingeimplantingeredraining. Peri-
cardiocentesis should be performed along the cardiac
tangent direction. Some effusion (60e100 mL) should be
drained. When the pericardial inner pressure is close to the
atmospheric pressure, the particles should be implanted.
Then, secondary draining can be performed. Given that the
particles are cylindrical, they spread with the beating heart
after implantation, and are drained out with the effusion
extraction.
In this study, the puncturingedraininge
implantingeredraining mode was conducive to ultrasonic
display, and could also reduce the toxicity of chemotherapy
particles against the heart. The 5-FU sustained-release
particles were implanted directly into the pericardial cav-
ity, and the released 5-FU directly faced the surface of the
heart. However, whether this process poses a threat to the
safety of a patient remains unknown. Through follow-up of
patients in the PI group, three patients exhibited palpita-
tion and suffocation 1 day after surgery, and these
symptoms improved after oxygen inhalation and oral
administration of metoprolol. This result does not indicate
that the patients were unsuitable for pericardial pressure
after effusion draining, but could be attributed to the first
release of 5-FU or the drug burst release-caused reaction.
Burst release refers to the transient high-concentration
drug release caused by the residual drugs among the par-
ticle microcapsule before the sustained-release formula-
tion reaches a releasing plateau in the releasing medium or
in vivo, which may lead to toxic drug levels in the body
[10e12]. Studies have suggested that the preparation
should undergo in vitro cleaning before entering the body.
In this study, the puncturingedrainingeimplantinge
redraining mode was equivalent to the in vitro cleaning
medicine. Although no patient had severe cardiac toxicity,
these results should be interpreted carefully. The longest
follow-up period of the patients using this therapy reached
5 years, and no complications, such as pericardial adhe-
sions, were found.
The 5-FU sustained-release PI therapy along the cardiac
tangent direction for MPCE treatment is classified as
ultrasound-guided intervention therapy, and is a novel
attempt in the field of interventional ultrasound. The
operation was simple, inexpensive, effective and reliable,
and did not result in radiation damage. Given that a limited
number of cases were included in this study, and the
follow-up time was short, the long-term effects of this
operation need further investigation.Acknowledgments
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